Newly onset cytopenias not always indicate a relapsing AML after allogeneic HSCT, a case of non-destructive post transplant lymphoproliferative disorder

Yiğit Kaya S., Askin A. E., Bektas S., ÇAKIR A., Gökmen Sevindik Ö. G.

LEUKEMIA RESEARCH REPORTS, cilt.19, 2023 (Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 19
  • Basım Tarihi: 2023
  • Doi Numarası: 10.1016/j.lrr.2023.100369
  • Dergi Adı: LEUKEMIA RESEARCH REPORTS
  • Derginin Tarandığı İndeksler: Scopus, Directory of Open Access Journals
  • Anahtar Kelimeler: Acute myeloid leukemia, Post transplant lymphoproliferative disorder, Epstein-Barr virus, Rituximab
  • İstanbul Medipol Üniversitesi Adresli: Evet

Özet

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains an effective option for the treatment of intermediate and high-risk Acute myeloid leukemia (AML). Post-transplant lymphoproliferative disorder (PTLD) is related to the intensity of post-transplant immunosuppression. Although Epstein-Barr virus (EBV) seropositivity and reactivation can be a major risk factor for PTLD. A few PTLDs could be EBV negative. There are a very limited number of PTLD cases following HSCT in patients with AML. We present a differential diagnosis of cytopenias after allo-HSCT. This is the first report of an AML patient developing bone marrow EBV-negative PTLD relatively late in their post-transplant course.